Springhill Offers Women A More Comfortable Mammography Experience
Springhill Medical Center is the only hospital in the area using the new Senographe Pristina™ by GE for the most comfortable mammography experiences our patients can have -- whether it’s our traditional 2D or with 3D Tomosynthesis technology. And, it’s ONLY available in Mobile at Springhill Medical Center!
Designed from the ground up with the input from women, it is the first mammography system to provide women with the “three Cs”: comfort, confidence, and clarity. The gentle, rounded corners of the image receptor, where the woman places her breasts, completely changes the experience of the traditional mammogram. Women can lean comfortably on the armrests, relaxing their muscles to simplify positioning, compression, and improve image quality.
The Senographe Pristina digital technology delivers superior diagnostic accuracy at the lowest radiation dose of all FDA-approved 3D mammography systems. Tomosynthesis, or 3D breast imaging, is an advanced technology in the fight against breast cancer that can be added to the regular 2D mammogram for an additional fee. It allows the radiologist to examine the breast tissue one layer at a time. The 3D imaging system uses high-powered computing to convert digital breast images into a stack of very thin layers or “slices.”
The ACS recommends that women with an average risk of breast cancer should undergo regular screening mammography as follows:
- Women should have the opportunity to begin annual screening between the ages of 40 and 44 years (qualified recommendation). Women should have annual screening starting at age 45 years (strong recommendation).
- Women aged 45 to 54 years should be screened annually (qualified recommendation).
- Women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually (qualified recommendation).
- Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer (qualified recommendation). The ACS does not recommend clinical breast examination for breast cancer screening among average-risk women at any age (qualified recommendation).
A Strong recommendation conveys the consensus that the benefits of adherence to the intervention outweigh the undesirable effects. A Qualified recommendation indicates there is clear evidence of benefit but less certainty about either the balance of benefits and harms, or about patients’ values and preferences, which could lead to different decisions about screening.